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Summary: A non-competitive Sandwich enzyme-linked immunosorbent assay for apolipoprotein C-I was
developed. Sheep antibody to this apolipoprotein C-I, purifled by affmity chromatography, was used for
coating the wells of a microtiter plate and äs a conjugate with alkaline phosphatase. The linear ränge of the
assay was from 80 ng to 15ng. It was sensitive down to 5ng. The intra-assay Variation coefficient was
2.8%, and the inter-assay Variation coefficient 5.3%. The mean concentration of apolipoprotein C-I was
61 ± 20 mg/1 in healthy normal males, and 65 + 19 mg/1 in females. Apolipoprotein C-I levels were positively
correlated with the total cholesterol concentration in both sexes (p < 0.002). A significant correlation with
triacylglycerol was only observed in males (p < 0.05). A significant increase of apolipoprotein C-I was
observed in type V hyperlipoproteinaemia, and in the only studied case of type III.
Enzymimmunoassay (ELISA) zur quantitativen Bestimmung von Apolipoprotein C-I
Zusammenfassung: Es wurde ein nicht kompetitiver enzymimmunometrischer Assay zur Bestimmung von
Apolipoprotein C-I entwickelt. Dabei gelangte der gleiche durch Affinitätschromatographie gereinigte Schaf-
anti-Apolipoprotein C-I-Antikörper sowohl zur Beschichtung von Mikrotiterplatten als auch als Enzymkonju-
gat mit alkalischer Phosphatase zu Anwendung. Der lineare Bereich der Methode lag zwischen 80 und 15 ng.
Sie war sensitiv bis 5 ng. Der Intra-assay-Variationskoeffizient betrug 2,8%, der Inter-assay-Variationskoeffi-
zient 5,3%. Bei gesunden männlichen Probanden wurde eine mittlere Apolipoprotein C-I-Konzentration von
61 + 20 mg/1 gemessen, bei Frauen eine mittlere Konzentration von 65 ± 19 mg/1. Die Apolipoprotein C-I-
Konzentration war positiv korreliert mit der Gesamtcholesterinkonzentration bei beiden Geschlechtern
(p < 0,002). Mit den Triglyceriden wurde eine signifikante Korrelation nur bei Männern beobachtet
(p < 0,05). In hyperlippproteinämischen Seren würde eine signifikante Zunahme der Apolipoprotein C-I-
Konzentration beim Typ V beobachtet und im einzigen untersuchten Fall einer Typ III-Hyperlipoproteinämie.
Introduction -
 sible for tfae hydrolysis of chylomicrons and VLDL.
Knowledge äbout the concentration of the C-apolipo- Deficiency of apolipoprotein C-II has been shown to
proteins, which — together with apolipoproteins B result in hypertriglyceridaemia (3). Apolipoprotein
and E — are majqr äpoproteins of triglyceride-rich C-III seems to prevent the hepatic uptake of triglyc-
lipoproteins, is rather liinited. Apolipoprotein C-II eride-rich lipoproteins (4, 5), and under certain exper-
and apolipoprotein C-III play an important rol© in imental conditions it is capable of inhibiting lipopro-
the degradation of triglyceride-rich lipoproteins, i. e. tein lipase (6, 7). The physiological significance of
chylomicrons and very low density lipoproteins apolipoprotein C-I is less well understood. The apoli-
(VLDL). Apolipoprotein C-II is an activator of the poprotein seems to activate the enzyme lecithin : cho-
enzyme lipoprotein lipase (l, 2), known to be respon- lesterpl acyl transferase (8), which is responsible for
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cholesterol esterification. This suggests that apolipo-
protein C-I, in contrast to the other C-apolipoprote-
ins is of importance in cholesterol metabolism. The
importance of the lecithin : cholesterol acyl transfer-
ase activation by apolipoprotein C-I in comparison
to its activation by apolipoprotein A-I is not yet
known. The quantitation of apolipoprotein C-I in
dyslipoproteinaemia is expected to provide further
insight into the biological role of this apolipoprotein.
The present report describes the development of a
non-competitive Sandwich enzyme-linked immuno-
sorbent assay (ELISA) for apolipoprotein C-I, and
the results obtained in normal and in hyperlipaemic
sera.
phosphate buffered saline, pH 7 A Optimal conditions for the
ELISA were found to be s follows: 200 μΐ Standard or serum
in duplicate, diiuted 2000 fold with phosphate buffered saline-
Tween, were pipetted into the wells of a precoated microtiter
plate. The covered plates were incubated for 2 hours at room
temperature and washed 5 times with phosphate buffered sa-
line-Tween. Two hundred microlitres of anti-apolipoprotein Ο-
Ι enzyme conjugate, diiuted 30 times with the same buffer,
were added per well and the plateS were incubated for 5 hours
at room temperature. Thereafter, the plates were washed 5
times with phosphate buffered saline-Tween and incubated with
/Miitrophenylphosphate (l g/l), 200 μΐ per well, until absorb-
ance for the highest concentration of the Standard was approxi-
mately 1.2. The reaction was then stopped by addition of
3 mol/1 NaOH and the developed colour was read at 405 nm
bn a Dynatech micro ELISA reader. Results were calculated by
logit-log transformation on a programmable HP 97 calculator.
Omega™ Lipid Fraction Control serum (Hyland Diagnostics)
was used s a secondary Standard, and R che™ Lipid Control
serum s the quality control.
Materials and Methods
Lipid analyses
Cholesterol and triglycerides were measured enzymatically in
a Technicon AA-II analyser, using reagents from Technicon
Instruments Corp. (Tarrytown, N. Y.).
Statistical analysis
The significance of the correlation coefficients was calculated
by means of the Human Statistic Dynamics Program (HSHU
Stats) on an Apple personal Computer.
Preparation of l ipoprotein density fractions
Very low density (VLDL), low density (LDL) and high density
lipoproteins (HDL) were prepared by a combination of precipi-
tation with Na-phosphotungstate-MgCl2 and ultracentrifuga-
tion s previously described by Burstein et al. (9).
Isolation of apolipoprotein and production of anti-
C-I antibodies
Apolipoprotein C-I was purified from apo VLDL by gel flltra-
tion on a column (2.5 cm χ 1.5 m) of Sephacryl S-200 superfine
in 6 mol/1 urea, 0.01 mol/1 Tris-HCl, pH 8.6. The peak contain-
ing apolipoprotein C-I was further purified by preparative
isoelectric focusing on Ultrodex (LKB, Bromma, Sweden) (10).
Apolipoprotein C-I was checked for purity by analytical isoelec-
tric focusing, SDS polyacrylamide gel electrophoresis, and
double immunodiffusion against anti-apolipoprotein B, anti-
apolipoprotein A-I and anti-apolipoprotein A-II, anti-apolipo-
protein C-II/C-III and anti-apolipoprotein E.
Sheep and rabbits were immunized with l mg of apolipoprotein
C-I in complete FreuncTs adjuvant and boosted in bi-weekly
intervals with the same amount of apolipoprotein C-I in incom-
plete Freuncfs adjuvant. Blood was taken after 2 weeks, 4 weeks
and 6 weeks. Anti-apolipoprotein C-I antibodies were isolated
by immunoadsorption on apolipoprotein C-I-Sepharose, pre-
pared by coupling of apolipoprotein C-I to pre-activated Sepha-
rose 4 B (Pharmacia, Uppsala); Protein concentration was
measured according to the method described by Bensadoun
(11).
Quantitation of apolipoprotein C-I by ELISA
Purified anti-apolipoprotein C-I was conjugated with alkaline
phosphatase (Boehringer Mannheim, FRG) according to pre-
vious publications (12, 13). For coating of the solid phase,
purified anti-apolipoprotein C-I at a concentration of 5 μg/200
μΐ per well was taken. Coating conditions were 37 °C for 3
hours, followed by 4°C overnight. Subsequently the plates
were washed 3 times with phosphate buffered saline-Tween 20
(0.05%), pH 7.4. Before use, the plates were saturated by means
of 200 μΐ/well of a solution of 1% bovine serum albumin in
Results
Induction of antibodies
Although apolipoprotein C-I is a rather small protein,
antibodies were readily developed with a titer of 100
to 200 mg/1. Upon repeated boosting, however, a
decrease in the antibody titer was observed. In addi-
tion, not every antibody preparation c uld be suc-
cessfully used in the non-competitive ELISA tech^
iiique. This is thought to be due to epitope Saturation
by the first (coating) antibody.
Standardization, sensitivity, precision and
accuracy of the apolipoprotein C-I ELISA
The Standard curves constructed with apolipoprotein
C-I, VLDL, LDL, HDL, apolipoprotein A-I, apoli-
poprotein Α-ΊΙ, apolipoprotein C-II, apolipoprotein
III and human serum albumin are illustrated in
figure 1. The curves prepared with isolated lipopro-
tein fractions and with apolipoprotein C-I had the
same slope. The same holds true for normal human
sera, for Omega™ and for the R che™ control
serum (not shown). The linear r nge of the apolipo-
protein C-I ELISA was from 80 ng to 15 ng, and it
was sensitive down to 5 ng. The assay was highly
specific, s indicated by the low crossnreaction with
the various proteins assessed, which never exceeded
1%. The precision of the assay is illustrated in table
1. The average intfa-assay coefficient of Variation
wajs 3.5%, arid the average inter-assay coefficient of
Variation 6.1%.
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Standard curves for the apolipoprotein C-I ELISA
(o) apolipoprotein C-I
(*) apolipoprotein C-II
(o) apolipoprotein C-III
(D) VLDL
( ) HDL
( ) LDL
(D) apolipoprotein A-I
( ) apolipoprotein A-II
(S) human serum albumin
Tab. l Precision of the apolipoprotein C-I ELISA
Apolipoprotein
C-I
(g/l)
0.107
0.051
Intra-assay CV
(n°= 10)
2.8
4.1
Inter-assay CV
(n°= 10)
5.3
6.8
The recoveries obtained by the ELISA technique after
addition of isolated apolipoprotein C-I in known
concentrations to a normal sefüm are given in table
2. The recoveries corresponded to the precision of
the assay, indicating a satisfactory accuracy of the
tests.
No difference was obtained when the sera were delipi-
dated with tetra-methyl-ürea (l -h l v/v) prior to
analysis, suggesting that the apolipoprotein C-I epito-
pes recognized by our antibody are fully exposed in
native lipoproteins.
The influence of storage on the' concentration of
apolipoprotein C^l was studied by assessing the apoli-
poprotein C-I levels in 3 different groups of sera: sera
stored for 2 to 3 months at -20 °C (n = 14), sera
stored for up to 4 years with repeated freezing and
thawing (N = 29) and fresh sera. All groups of sera
had similar levels of cholesterol and triglycerides. The
mean apolipoprotein C-I value did not significantly
differ between the 3 groups of sera, indicating that
storage at — 20 °C even over several years has no
significant influence on the concentration of apolipo-
protein C-I in our assay.
Apolipoprotein C-I levels in normal blood
donors
Table 3 summarizes the serum concentration of apoli-
poprotein C-I in normal males and females of similar
age (males: 55 + 13, females: 52 + 15 years old).
The difference between both groups was statistically
not significant.
Tab. 3. Concentration of apolipoprotein C-I, total serum cho-
lesterol
 %and triglycerides in apparently healthy males
and females
Sex
Male
Female
n
38
32
Apolipo-
protein
C-I (g/l)
0.061 ± 0.020
0.065 ± 0.019
Total
cholesterol
(mmol/1)
5.2 + 0.8
5.4 ± 0.6
Triglycerides
(mmol/l)
1.5± 0.4
1.5 ± 0.3
Apolipoprotein C-I levels correlated significantly
with the total cholesterol concentration in both sexes
(males: r = 0.45, p < 0.001; females: r = 0.47, p <
0.002). In cpntrast, the correlation between apolipo-
protein C-I and the triglycerides only reached signifi-
cance in males (r = 0.35, p < 0.05). In females
these two parameters were not significantly correlated
(r = 0.23, p = 0.21).
The qüantitation of apolipoprotein C-I in the dif-
ferent lipoprotein density fractions indicates that this
apolipoprotein predominates in the VLDL class. Fif-
teen per cent of the total protein content of this
fraction consisted of apolipoprotein C-I. In LDL,
apolipoprotein C-I made up 0.1% of the protein part,
in HDL 1.7%.
Tab. 2. Accuracy of the ELISA for apolipoprotein C-I
Apolipöprotein C-I
in 'serum (g/l)
0.061
0.061
0.061
Apolipoprotein C*I
added (g/l)
0.054
0.111
0;147
Apolipoprptein C-I
expected (g/l)
0.115
0.172
0.208
Apolipoprotein C-I
found (g/l)
0.117
0.163
0.216
Recovered (%)
102
95
104
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Tab. 4. Apolipoprotein C-I and lipid levels in patients with different types of hyperlipoproteinaemia
Type
I
11 a
II b
III
IV
V
*)P
**)P
n
5
31
30
1
24
23
<0.05
< 0.01
Apolipoprotein
C-I (g/l)
0.061 + 0.041
0.072 + 0.022
0.069 -l· 0.029
0.148
0.086 + 0.039
0.123 + 0.062
Triglycerides
/ 1 /1\(mmol/1)
12.5 ± 1.7
1.6 ± 0.3
2.7 + 0.8
11.6
5.4+ 2.5
17.5 + 10.9
Cholesterol
/•M «V» .1 /1\(mmol/1)
4.5 + 0.9
8.3 ± 1.6
7.7 + 0.9
18.0
6.6 + 1.3
12.1 + 5.4
Correlation r
Apolipoprotein C-I/
Triglycerides
0.74
-0.06 ' f
0.09
—
0.23 .
O.ÖO
Apolipoprotein C-I/
Cholesterol
0.86
-0.07
0.39*)
—
0.50**)
0.39*)
Apolipoprotein C-I levels in hyperlipopro-
teinaemia
The level of apolipoprotein C-I in the different types
of hyperlipoproteinaemia and its correlation to the
concentration of total serum Cholesterol and trigly-
cerides are summarized in the table 4. A significant
increase in \ the mean apolipoprotein C-I concentra-
tion was observed in type V hyperlipoproteinaemia
(p < 0.05) and in the serum of the only patient with
type III hyperlipoproteinaemia (apolipoprotein C-I
level: 0.148 g/l). In the other types, the mean apolipo-
protein C-I concentration was comparable to values
observed in normal blood donors. A significant corre-
lation was found between apolipoprotein C-I and
total cholesterol in all types, with the exception of
type II a hyperlipoproteinaemia, while no significant
correlation was observed with the triglycerides.
Discussion
This report describes the development of a sandwich-
ELISA for the quantitative determination of apolipo-
protein C-I in serum and in isolated lipoprotein den-
sity fractions. The results obtained with this assay
show good precision, high sensitivity and appropriate
accuracy. So far, the quantitative determination of
apolipoprotein C-I by immunoassay has been re-
ported only once (14), using electroimmunodiffusion.
Our data are in good agreement with these values.
The ELISA offers some advantages over electroim-
munodiffusion: it is more sensitive and it does not
depend on a Standard with the same migration
properties äs the serum. This may be particularly
crucial with very large molecules like VLDL, which
are known to transport the major part of the C-
apolipoproteins. The Standard curves obtained with
isolated apolipoprotein C-I, native serum and isolated
lipoprotein density classes were found to be parallel,
indicating immunological identity of apolipoprotein
C-I in each lipoprotein class. Delipidation of the
serum did not increase the amount of apolipoprotein
C-I äs measured by our polyclonal antibody. This
indicates that the apolipoprotein C-I epitopes are
fülly exposed to the antibodies in this assay system.
Lipid and lipoprotein levels are known to be in-
fluenced by sex hormones (15). Differences between
males and females have been noted for the level of
most apolipoproteins by maiiy authors, i. e. apolipo-
protein B (16), apolipoprotein A-I (17—21), apolipo-
protein A-II (18, 20), for apolipoprotein C-III (22)
and for apolipoprotein E (23). So far no data about
the level of apolipoprotein OI in males and females
are known. Our results indicate thät apolipoprotein
C-I differs from most other lipoproteins, in that its
serum level shows remarkably similar values in both
sexes.
Our finding was that 15% of the protein part of
VLDL consists of apolipoprotein C-I. According to
Kashyap et al., apolipoprotein C-III makes up 18%
of apo VLDL (24). This would leave about 12%
for apolipoprotein C-II if one assumes that the C-
apolipoproteins contribute about 45% of the VLDL-
proteins. This seems to be a reasonable distribution.
Since the C-apolipoproteins constitute the major pro^
tein part of VLDL, one would expect a close correla-
tion between the level of the triglycerides, which
essentially are transported within this lipoprotein
class, and the concentration of the C-apolipoproteins.
Indeed, such a correlation was observed for apolipo-
protein C-III (22, 24, 25). Surprisingly, a significant
correlation was found between apolipoproteifi CJ
and total cholesterol in both sexes, while the correla-
tion between apolipoprotein C-I and triglycerides
reached the level of significance only in normal men.
This might be due to the fact that'triglycerides are
transported apart from VLDL in chylomicrons which
do not contäin very much protein. Therefqre apolipo-
protein C-I levels were correlated to VLDL-choles-
terol and -triglycerides. Howeyer, no substantial in-
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erease of the correlation coefficients between apolipo-
protein C-I and VLDL-triglycerides was observed in
either type IV nor type V hyperlipoproteinaemia,
while the correlation coefficient between apolipopro-
tein C-I and VLDL-cholesterol was slightly increased
äs compared to total cholesterol.
In contrast to apolipoprotein C-III, which seems to
be increased in all types of hyperlipoproteinaemia
(22, 25), a significant increase of apolipoprotein C-I
was only observed in type V hyperlipoproteinaemia.
The observed correlation between apolipoprotein C-
I and total cholesterol was present in all types of
hyperlipoproteinaemia, with the exception of pure
hypercholesterolaemia (type II a). This is rather unex-
pected, since apolipoprotein C-I levels were only in-
creased in type V hyperlipoproteinaemia. At present
we have no explanation for this observation. The
finding of an association between apolipoprotein C-
I and the total serum cholesterol concentration may
be of interest in view of the ability of apolipoprotein
C-I to activate lecithin: cholesterol acyl transferase
(8), which mediates the formation of cholesterol esters
from unesterified cholesterol and phosphatidyl cho-
line (26). Our data might therefore suggest that apoli-
poprotein C-I plays a much more important role in
lipoprotein metabolism than previously thought. The
observation of a rather indifferent level of apolipo-
protein C-I in the different types of hyperlipoprote-
inaemia (with the exception of type V), however, is
not in favour of such a hypothesis. Further studies
on the concentration of apolipoprotein C-I and on
its distribution within the various density classes of
lipoproteins in different types of diseases will be
needed in order to get more insight into the physio-
logical significance of apolipoprotein C-I.
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